As well as research into primary immunodeficiencies, it is also conducting research to identify molecular bases in cases of less serious combined immunodeficiencies that have not yet been characterised by exogenous analysis or high-performance sequencing techniques, next generation sequencing (NGS). The group is jointly responsible for implementing the RAPID programme (Rapid and Advanced diagnosis and treatment of Primary ImmunoDeficiencies), which includes the use of NGS to reduce the time between clinical suspicion and genetic diagnosis. An example of collaboration between the Hospital, the Vall d’Hebron Research Institute and the BST (Banc de Sang i de Teixits - Blood and Tissue Bank) to coordinate all the stages in managing patients with these pathologies.

The group is also working in connection with other research groups and with industry to identify better biomarkers  for  a variety of immune-mediated diseases in order to evaluate therapeutic activity and response in autoimmune diseases. 

This group coordinates the Barcelona-UAB-Focis (Federation of Clinical Immunology Societies) Centre of Excellence.

Visit the research group’s page


Subscribe to our newsletters and be a part of Vall d'Hebron Campus

Select the newsletter you want to receive:

By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Vall d’Hebron University Hospital Foundation – Research Institute.
Purpose: Manage the user’s contact information.
Legitimisation: Express acceptance of the privacy policy.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.